CVRx reported second-quarter 2026 revenue of $15.7 million, a 16% increase from the prior year, but lowered its full-year revenue guidance to between $58.0 million and $60.0 million. U.S. revenue rose 21% to $14.8 million, driven by growth in heart failure implants and expansion to 258 active implanting centers, while European revenue fell 31% to $0.9 million. The company cited fewer sales territories than anticipated, lower sales force productivity, and a prolonged challenge with one of its largest payers as reasons for the reduced outlook. Gross margin improved to 87%, and net loss narrowed to $14.0 million, or $0.53 per share. Humana issued a Medicare Advantage coverage policy for Barostim therapy effective May 1, 2026, marking the first coverage policy of its kind for the device.
CVRx IncCuts full-year revenue outlook due to lower sales force productivity and fewer territories, despite Q2 growth.
Humana IncHumana issued a Medicare Advantage coverage policy for Barostim therapy, a positive regulatory development.
